Renaldee AG

Renaldee’s lead asset, Solrena®, is a first-in-class, plant-derived active Vitamin D therapy addressing major unmet needs in chronic kidney disease (CKD) and osteoporosis.

Solrena® is a purified, standardized extract of Solanum glaucophyllum, enriched in 1,25-dihydroxyvitamin D3 glycosides, the biologically active form of vitamin D that delivers full physiological function. Its unique glycoform clearly differentiates Solrena® from conventional vitamin D products and supports its development as a prescription drug candidate.

Because active vitamin D deficiency is central to CKD pathophysiology, Renaldee is initially focusing on CKD for regulatory and clinical efficiency, with osteoporosis as a follow-on indication to expand the commercial opportunity.